Neuroprotection during chemotherapy: a systematic review.
The development of neurotoxicity during antineoplastic therapy is one of the most common reasons for termination or modification of cancer treatment. A number of different agents have been proposed to provide neuroprotection without affecting antitumor efficacy. This review provides an evidence-based summary of neuroprotective medicines, an overview of the literature relating to neuroprotection during cancer treatment and a Neurologist perspective risk assessment and management. Through a systematic review the authors identified 49 papers published to date that report human clinical trials involving potential neuroprotectants in adults. Case reports and series completed in a prospective fashion were also included. Sensory neuropathies were the most prevalent subtype in the literature, and most were at least partially reversible with or without neuroprotective treatment. The majority of study medications had minimal side effects, though 2 trials were prematurely terminated because of adverse patient outcomes. No study reported an effect on antitumor efficacy. Because of the variability in study design, cancer type, outcome measures, and clinical confirmation of neuropathy, meta-analysis could not be appropriately performed. We highlight risk factors and discuss neuropathy screening. Descriptive analysis is provided which reveals that many of the agents studied were likely to confer some at least some neuroprotective benefit.
Walker
Melanie
M
Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA. walkerm@u.washington.edu
Ni
Oliver
O
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D009420:Nervous System / Q000187:drug effects / Q000473:pathology*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009498:Neurotoxins / Q000627:therapeutic use / Q000633:toxicity
D000970:Antineoplastic Agents; D018696:Neuroprotective Agents; D009498:Neurotoxins